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O.R. & 95% CI
(GO : No GO)
Favourable:
CC 12/25 8/20 −1·0 4·9 0.82 (0.34, 1.98)
CT 5/18 6/12 −1·7 2·6 0.52 (0.15, 1.74)
TT 1/4 4/4 −1·9 1·2 0.19 (0.03, 1.19)
Subtotal: 18/47 18/36 −4·6 8·7 0.59 (0.30, 1.14)
P = 0·1
Test for heterogeneity between subgroups: χ22 = 2·0; P = 0·4                                                                             
Test for trend between subgroups: χ21 = 1·9; P = 0·2
Intermediate:
CC 42/69 36/58 −1·0 19·2 0.95 (0.61, 1.49)
CT 42/62 37/64 4·2 19·7 1.24 (0.80, 1.93)
TT 8/16 4/7 −0·9 2·3 0.68 (0.19, 2.47)
Subtotal: 92/147 77/129 2·3 41·2 1.06 (0.78, 1.44)
P = 0·7
Test for heterogeneity between subgroups: χ22 = 1·2; P = 0·6                                                                             
Test for trend between subgroups: χ21 = 0·1; P = 0·8
Adverse:
CC 14/14 8/8 −0·7 4·3 0.85 (0.33, 2.19)
CT 13/15 7/8 0·6 4·7 1.15 (0.46, 2.83)
TT 3/4 1/1 −0·8 0·2 0.01 (0.00, 0.90)
Subtotal: 30/33 16/17 −0·9 9·1 0.91 (0.48, 1.74)
P = 0·8
Test for heterogeneity between subgroups: χ22 = 4·1; P = 0·1                                                                             
Test for trend between subgroups: χ21 = 0·1; P = 0·8




Effect P = 0·7
Test for heterogeneity (9 groups): χ28 = 9·8; P = 0·3                                                                                    
Test for trend between subtotals: χ21 = 0·8; P = 0·4
Test for heterogeneity between subtotals: χ22 = 2·5; P = 0·3                                                                             
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O.R. & 95% CI
(GO : No GO)
Favourable:
CC 7/26 7/22 −0·8 3·4 0.79 (0.27, 2.27)
CT 4/18 6/13 −2·5 2·2 0.33 (0.09, 1.23)
TT 0/4 3/4 −1·6 0·7 0.12 (0.01, 1.12)
Subtotal: 11/48 16/39 −4·9 6·4 0.47 (0.22, 1.01)
P = 0·05
Test for heterogeneity between subgroups: χ22 = 2·7; P = 0·3                                                                             
Test for trend between subgroups: χ21 = 2·6; P = 0·1
Intermediate:
CC 38/75 40/67 −5·4 19·0 0.75 (0.48, 1.18)
CT 46/73 28/67 11·7 18·3 1.90 (1.20, 3.00)
TT 9/18 8/11 −2·6 3·7 0.49 (0.18, 1.38)
Subtotal: 93/166 76/145 3·7 40·9 1.10 (0.81, 1.49)
P = 0·6
Test for heterogeneity between subgroups: χ22 = 10·5; P = 0·005                                                                          
Test for trend between subgroups: χ21 = 1·1; P = 0·3
Adverse:
CC 15/16 14/14 −4·8 5·7 0.43 (0.19, 0.97)
CT 17/19 12/13 0·0 6·9 1.00 (0.48, 2.11)
TT 4/6 1/1 −0·5 0·4 0.31 (0.02, 6.40)
Subtotal: 36/41 27/28 −5·3 13·0 0.67 (0.39, 1.14)
P = 0·1
Test for heterogeneity between subgroups: χ22 = 2·5; P = 0·3                                                                             
Test for trend between subgroups: χ21 = 1·2; P = 0·3




Effect P = 0·4
Test for heterogeneity (9 groups): χ28 = 21·2; P = 0·007                                                                                 
Test for trend between subtotals: χ21 = 0·0; P = 0·9
Test for heterogeneity between subtotals: χ22 = 5·5; P = 0·06                                                                            
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